FOR IMMEDIATE RELEASE

      MAJORITY OF BRAINSTORM SHAREHOLDERS REAFFIRM THEIR AGREEMENT TO A
"LOCK-UP" OF THEIR STOCK

      -     DEMONSTRATING CONFIDENCE IN COMPANY'S SHORT- AND LONG-TERM GOALS


TEL AVIV, ISRAEL - MARCH 22, 2005 - BRAINSTORM CELL THERAPEUTICS (OTC BB:
BCLI.OB), AN EMERGING COMPANY IN STEM CELL THERAPEUTICS FOR NEURODEGENERATIVE
DISEASES, today announced that the Company has received signed confirmations
from holders of 15,290,000 shares of Company Common Stock, representing 73.2% of
the Company's issued and outstanding shares of Common Stock to a "lock-up"
agreement with respect to their shares, which were purchased in July 2004.

Specifically, such shareholders agreed that eighty-five percent (85%) of the
covered shares shall be restricted from transfer for a twenty-four month period
from July 8, 2004 and fifteen percent (15%) of the covered shares shall be
restricted for a twelve month period from such date. In addition, Ramot at Tel
Aviv University Ltd. and their designees have agreed to the same restrictions on
a total of 12,800,844 warrants, which were granted to them under the technology
licensing agreement.

Dr. Yaffa Beck, CEO of BrainStorm commented, "We are very pleased with these
agreements and believe that they reflect our shareholders' long-term perspective
and confidence in the company."

For more information, visit the Company's website at www.brainstorm-cell.com.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.

BrainStorm Cell Therapeutics Inc. is an emerging company developing neural-like
stem cell therapeutic products, NurOwn(TM), based on autologous bone marrow
derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM)
patent pending technology is based on discoveries made by the team of prominent
neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and
expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research
Center of Tel-Aviv University, enabling the differentiation of bone marrow
derived stem cells into functional neurons, as demonstrated in animal models.
The company holds rights to develop and commercialize the technology through an
exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd.,
the technology transfer company of Tel Aviv University. The company's initial
focus is on developing treatments for Parkinson's Disease.



ABOUT STEM CELL THERAPY

Stem cells are non-specialized cells with a remarkable potential for both
self-renewal and differentiation into cell types with a specialized function,
such as muscle, blood or brain cells. Stem cells may be sourced from fetal or
embryonic tissue or from adult tissue reservoirs such as bone marrow. Use of
embryonic stem cells, has become the center of significant ethical and moral
debate. In contrast, use of adult stem cells does not face the same moral or
legal controversy. Stem cell therapy aims to "cure" disease by replacing the
'diseased' cells with 'healthy' cells derived from stem cells. This approach has
the potential to revolutionize medicine and, if successful, the implied
commercial opportunities are great. Currently, both embryonic stem cells (ESC)
and adult stem cells (ASC) are being explored as the potential basis for
multiple cell therapy products.

ABOUT PARKINSON'S DISEASE

Parkinson's Disease (PD), which was first described by James Parkinson in 1817
as "the shaking palsy", is a chronic, progressive neurodegenerative disorder,
affecting the brain cells responsible for production of dopamine. The symptoms
include tremors, rigidity, slowness of movement and impaired balance. Over four
million people in the developed world, including as many as 1.5 million
Americans, mainly over the age of 65, are diagnosed with PD. That figure is
predicted to rise by 10% by 2010. Pharmaceutical treatments of PD with an
estimated combined annual market value of $4 billion, are insufficient to meet
patient needs. The search for more effective treatments continues.

SAFE HARBOR STATEMENT:

Statements in this announcement other than historical data and information
constitute "forward-looking statements" and involve risks and uncertainties that
could cause BrainStorm Cell Therapeutics Inc. actual results to differ
materially from those stated or implied by such forward-looking statements. The
potential risks and uncertainties include, among others, risks associated with
BrainStorm Cell Therapeutics Inc. limited operating history, history of losses
and expectation to incur losses for the foreseeable future; need to raise
additional capital to execute on its business plan; dependence on its license to
Ramot's technology and ability to meet its funding and payment obligations
included in such license agreement; ability, together with its licensor, to
adequately protect the NurOwn(TM) technology; dependence on key executives who
have recently joined the company and on its scientific consultants; ability to
identify, negotiate and successfully implement strategic partnering
relationships; ability to complete clinical trials successfully and to obtain
required regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining regulatory approval
for treatments in BrainStorm Cell Therapeutics Inc. market; the limited public
trading market for BrainStorm Cell Therapeutics Inc. stock which may never
develop into an active market; and other factors detailed in BrainStorm Cell
Therapeutics Inc. annual report on From 10-KSB, quarterly reports on Form
10-QSB, current reports on From 8-K and other filings with the Securities and
Exchange Commission available at http://www.sec.gov/ or by request to the
Company.